Elixxer

Elixxer Debt

The Debt of Elixxer (ELXR.H.V) as of Nov 15, 2026 is 9.66 M CAD. In the previous year, Debt was 8.02 M CAD — a change of 20.40% (higher).

Debt

9.66 MCAD

YoY

20.40%

Last updated:

In 2023, Elixxer's total debt was 9.66 M CAD, a 20.40% change from the 8.02 M CAD total debt recorded in the previous year.

The Elixxer Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2016
0.00 CAD
Jan 1, 2017
325,000.00 CAD
Jan 1, 2018
2.53 M CAD
Jan 1, 2019
8.14 M CAD
Jan 1, 2020
13.09 M CAD
Jan 1, 2021
6.54 M CAD
Jan 1, 2022
8.02 M CAD
Jan 1, 2023
9.66 M CAD
The Elixxer Debt history
YEARDebtYoY
9.66 MCAD+20.40%
8.02 MCAD+22.56%
6.54 MCAD-50.01%
13.09 MCAD+60.80%
8.14 MCAD+222.00%
2.53 MCAD+678.06%
325,000.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

Debt Details

Understanding Elixxer's Debt Structure

Elixxer's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Elixxer's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Elixxer’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Elixxer’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Elixxer stock

Debt of Elixxer is 9.66 M CAD in 2023.

Debt of Elixxer changed from 8.02 M CAD to 9.66 M CAD, representing a 20.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Elixxer since 2006 – with annual values, charts, and detailed analysis.

Debt's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Elixxer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Elixxer

All Key Metrics — Elixxer